Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Russian bladder cancer care under the microscope: new study tracks Real-World treatments

NCT ID NCT07038928

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 15, 2026 · Updated 5 times

Summary

This study is observing how bladder cancer is treated in Russia and how common certain markers (HER2 and PD-L1) are in different stages. Researchers will look at medical records of 600 people with bladder cancer to see what treatments they receive and how the disease progresses. The goal is to understand current care patterns, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Planned study population consists of approximately 600 adult patients with urothelial bladder cancer. Patients who were diagnosed with urothelial bladder cancer and satisfy the additional eligibility criteria as assessed by the investigator will be invited to participate during routine clinical visit. Only patients who will give their written informed consent will be included. Consecutive patients included in the study will form three study cohorts of equal size (around 200 participants each) according to the stages of urothelial bladder cancer at the time of study inclusion: high-risk NMIBC, MIBC, and mBC.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years; * Signed ICF, including consent for FFPE tumor tissue sample testing; * Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry; * For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature: * T1 tumor * High grade/G3 tumor * CIS (carcinoma in situ) * Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point); * For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry; * For patients with mBC: mBC diagnosed during 12 months prior to study entry; * Availability of medical history data; * Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery. Exclusion Criteria: • Participation in any interventional trial since the urothelial bladder cancer diagnosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bladder cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Arkhangelsk, Russia

  • Research Site

    RECRUITING

    Barnaul, Russia

  • Research Site

    RECRUITING

    Chelyabinsk, Russia

  • Research Site

    RECRUITING

    Krasnodar, Russia

  • Research Site

    RECRUITING

    Krasnoyarsk, Russia

  • Research Site

    RECRUITING

    Makhachkala, Russia

  • Research Site

    RECRUITING

    Moscow, Russia

  • Research Site

    WITHDRAWN

    Moscow, Russia

  • Research Site

    NOT_YET_RECRUITING

    Moscow, Russia

  • Research Site

    RECRUITING

    Nizhny Novgorod, Russia

  • Research Site

    WITHDRAWN

    Novosibirsk, Russia

  • Research Site

    NOT_YET_RECRUITING

    Obninsk, Russia

  • Research Site

    RECRUITING

    Omsk, Russia

  • Research Site

    RECRUITING

    Saint Petersburg, Russia

  • Research Site

    NOT_YET_RECRUITING

    Saint Petersburg, Russia

  • Research Site

    WITHDRAWN

    Saint Petersburg, Russia

  • Research Site

    RECRUITING

    Tomsk, Russia

  • Research Site

    RECRUITING

    Tyumen, Russia

  • Research Site

    RECRUITING

    Ufa, Russia

  • Research Site

    RECRUITING

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.